Pacira BioSciences Inc (NASDAQ: PCRX) has reported E.P.S. of $0.19 for its first fiscal quarter (ending March 31) versus $-0.43 for the same period a year ago. Relative to the consensus estimate of $0.79, this was a shortfall of $-0.60. For the latest four quarters through March 31, E.P.S. were $1.52 compared to $-0.23 a year ago.
Recent Price Action
Pacira BioSciences Inc (NASDAQ: PCRX) stock closed at $26.51 on 5/7/24 after a slight gain of 0.04%. Moreover, this advance was accompanied by unusually high trading volume at 153% of normal. The stock has risen 1.8% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, PCRX is expected to continue to be an important Value Builder.
Pacira BioSciences has a current Value Trend Rating of D (Negative). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Pacira BioSciences has a slightly positive Appreciation Score of 64 but a very low Power Rating of 13, triggering the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment